<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920192</url>
  </required_header>
  <id_info>
    <org_study_id>111645</org_study_id>
    <nct_id>NCT00920192</nct_id>
  </id_info>
  <brief_title>Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer</brief_title>
  <official_title>A Phase 1/2, Open-Label, Multicenter Study of GSK1363089Gin Adult Subjects With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of foretinib (also known&#xD;
      as GSK1363089) when used in the treatment of patients with advanced hepatocellular carcinoma&#xD;
      (liver cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to identify the maximum tolerated dose (MTD) of foretinib (also&#xD;
      known as GSK1363089) when used in the treatment of patients with advanced hepatocellular&#xD;
      carcinoma (liver cancer), and to assess the safety and tolerability of that dose in this&#xD;
      patient population.&#xD;
&#xD;
      The MTD will be identified during Phase I, by standard dose-escalation of foretinib. Then&#xD;
      Phase II will assess the safety and tolerability of foretinib dosed at MTD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2009</start_date>
  <completion_date type="Actual">March 24, 2015</completion_date>
  <primary_completion_date type="Actual">March 7, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD)</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of foretinib at the MTD as measured by number and severity of AEs</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The antitumor activity of foretinib at the MTD according to RECIST</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of foretinib</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Foretinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I starting dose of 30 mg/day escalated to 45 mg/day, de-escalated to 30 mg/day; MTD for Phase II was 30 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foretinib</intervention_name>
    <description>Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,</description>
    <arm_group_label>Foretinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0 or 1&#xD;
&#xD;
          -  Has histologically or cytologically confirmed advanced (unresectable and/or&#xD;
             metastatic) hepatocellular carcinoma (HCC).&#xD;
&#xD;
          -  Has adequate organ system function&#xD;
&#xD;
          -  Has at least 1 target tumor lesion.&#xD;
&#xD;
          -  Has the ability to swallow and retain oral medication&#xD;
&#xD;
          -  Has a life expectancy of at least 12 weeks&#xD;
&#xD;
          -  If male:&#xD;
&#xD;
        Agrees to use double-barrier contraception, OR Agrees to complete abstinence from sexual&#xD;
        intercourse for 14 days before exposure to investigational product, during the clinical&#xD;
        trial, and for at least 21 days after the last dose of investigational product&#xD;
&#xD;
        - If female: Is of nonchildbearing potential OR Is of childbearing potential and has a&#xD;
        negative serum pregnancy test within 14 days before the first dose of study drug, and&#xD;
        agrees to use adequate contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has previously used an investigational agent or licensed drug that inhibits multiple&#xD;
             receptor tyrosine kinases&#xD;
&#xD;
          -  Is currently receiving cancer therapy&#xD;
&#xD;
          -  Is currently receiving treatment with an investigational agent, including an&#xD;
             investigational anticancer agent&#xD;
&#xD;
          -  Has a Child-Pugh score &gt;6&#xD;
&#xD;
          -  Has AEs due to investigational drugs or other medications administered more than 21&#xD;
             days before enrollment that have not recovered to Grade 1 or less with the exception&#xD;
             of alopecia greater than Grade 1&#xD;
&#xD;
          -  Has received local therapy within the following timeframes and the subject has not&#xD;
             fully recovered from the prior therapy: Radiotherapy: less than 28 days since&#xD;
             completion of prior radiotherapy Chemoembolization, hepatic arterial embolization,&#xD;
             percutaneous ethanol injection, or cryoablation: less than 42 days since completion of&#xD;
             prior therapy Radiofrequency ablation: less than 60 days since completion of prior&#xD;
             therapy Surgery: (1) prior surgical procedure affecting absorption, and (2) less than&#xD;
             28 days since last prior major surgery&#xD;
&#xD;
          -  Has a history or clinical evidence of central nervous system metastases or&#xD;
             leptomeningeal carcinomatosis&#xD;
&#xD;
          -  Has a history of malabsorption syndrome, any medical condition significantly affecting&#xD;
             gastrointestinal function, or resection of the stomach or small bowel&#xD;
&#xD;
          -  Has active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal&#xD;
             condition increasing the risk of perforation, or history of abdominal fistula,&#xD;
             gastrointestinal perforation, or intra-abdominal abscess within the past 28 days&#xD;
&#xD;
          -  Has a known immediate or delayed hypersensitivity or idiosyncratic reaction to drugs&#xD;
             chemically related to foretinib.&#xD;
&#xD;
          -  Has a QTcB (Bazett-corrected QT interval) or QTcF (Frederica-corrected QT interval)&#xD;
             greater than or equal to 470 msec (or 500 msec if the subject has bundle branch&#xD;
             block).&#xD;
&#xD;
          -  Has a history of any one of the following cardiac conditions or procedures within the&#xD;
             past 6 months: Cardiac angioplasty or stenting Myocardial infarction Unstable angina&#xD;
&#xD;
          -  Has a history of a cerebrovascular accident within the past 6 months&#xD;
&#xD;
          -  Has Class III or IV heart failure as defined by the New York Heart Association&#xD;
             functional classification system&#xD;
&#xD;
          -  Has poorly controlled hypertension (systolic blood pressure of 140 mm Hg or greater or&#xD;
             diastolic blood pressure of 90 mm Hg or greater)&#xD;
&#xD;
          -  Has a history of untreated deep venous thrombosis within the past 6 months (e.g., calf&#xD;
             vein thrombosis)&#xD;
&#xD;
          -  Has a history of main portal vein thrombosis&#xD;
&#xD;
          -  Has the presence of any nonhealing wound, fracture, or ulcer, or the presence of&#xD;
             symptomatic peripheral vascular disease&#xD;
&#xD;
          -  Has had previous or concurrent cancer that is distinct in primary site or histology&#xD;
             from HCC, except cervical carcinoma in situ, treated basal cell carcinoma, and&#xD;
             superficial bladder tumors (tumor stages Ta, Tis, and T1). Any cancer curatively&#xD;
             treated more than 3 years before study entry is permitted.&#xD;
&#xD;
          -  Has a history of bleeding varices within the past 30 days&#xD;
&#xD;
          -  Has had clinically significant gastrointestinal bleeding within the past 30 days&#xD;
&#xD;
          -  Is a pregnant or lactating female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tainan</city>
        <zip>70428</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c-MET</keyword>
  <keyword>VEGFR2</keyword>
  <keyword>Advanced hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111645</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111645</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111645</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111645</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111645</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111645</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

